Table I. Patient characteristics.
CA19-9: Carbohydrate antigen 19-9; CEA: carcinoembryonic antigen; GnP: gemcitabine with nab-paclitaxel; mFFX: modified FOLFIRINOX; PS: performance status. *3 cases remained on first-line chemotherapy.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.